We assessed robustness and reproducibility of the cuprizone mouse model of de- and remyelination for its use in testing novel pharmacological treatments of demyelinating disorders such as multiple sclerosis. In several multimodal MRI studies using independent batches of animals, increases in T2, decreases in MTR and FA and biphasic responses in MK upon cuprizone feeding, as well as partial recoveries after cuprizone withdrawal, showed huge effect sizes and high cross-study consistency, especially in the corpus callosum. Our results substantiate the suitability of the cuprizone mouse model for longitudinal monitoring of the pathology using multimodal MRI.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords